Apogee Therapeutics Inc (NASDAQ: APGE) is -2.63% lower on its value in year-to-date trading and has touched a low of $26.20 and a high of $63.50 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The APGE stock was last observed hovering at around $36.41 in the last trading session, with the day’s gains setting it 0.61%.
Currently trading at $37.02, the stock is -12.42% and -7.54% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.7 million and changing 1.68% at the moment leaves the stock -14.43% off its SMA200. APGE registered -18.28% loss for a year compared to 6-month loss of -22.50%. The firm has a 50-day simple moving average (SMA 50) of $40.0369 and a 200-day simple moving average (SMA200) of $43.26275.
The stock witnessed a -9.66% gain in the last 1 month and extending the period to 3 months gives it a 14.61%, and is -16.36% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.90% over the week and 6.97% over the month.
Apogee Therapeutics Inc (APGE) has around 196 employees, a market worth around $2.20B and $0.00M in sales. Distance from 52-week low is 41.30% and -41.70% from its 52-week high. The company has generated returns on investments over the last 12 months (-30.15%).
The EPS is expected to shrink by -32.05% this year
242.0 institutions hold shares in Apogee Therapeutics Inc (APGE), with institutional investors hold 149.07% of the company’s shares. The shares outstanding are 46.04M, and float is at 37.32M with Short Float at 24.59%. Institutions hold 137.71% of the Float.
The top institutional shareholder in the company is VR ADVISER, LLC with over 8.49 million shares valued at $334.21 million. The investor’s holdings represent 15.0284 of the APGE Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 7.51 million shares valued at $295.36 million to account for 13.2812 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 3.55 million shares representing 6.2761 and valued at over $139.57 million, while BLACKROCK INC. holds 4.8528 of the shares totaling 2.74 million with a market value of $107.92 million.
Apogee Therapeutics Inc (APGE) Insider Activity
The most recent transaction is an insider sale by Dambkowski Carl, the company’s Chief Medical Officer. SEC filings show that Dambkowski Carl sold 10,090 shares of the company’s common stock on Jul 02 ’25 at a price of $45.09 per share for a total of $0.45 million. Following the sale, the insider now owns 0.24 million shares.
Still, SEC filings show that on Jun 04 ’25, Dambkowski Carl (Chief Medical Officer) disposed off 2,725 shares at an average price of $36.96 for $0.1 million. The insider now directly holds 241,723 shares of Apogee Therapeutics Inc (APGE).
